financetom
Business
financetom
/
Business
/
Wilmington Capital Management Swings to Loss in Q4, Revenue Falls; Declares Special Dividend
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wilmington Capital Management Swings to Loss in Q4, Revenue Falls; Declares Special Dividend
Mar 7, 2024 4:24 AM

07:11 AM EST, 03/07/2024 (MT Newswires) -- Wilmington Capital Management (WCM-A.TO, WCM-B.TO) overnight Wednesday reported a fourth-quarter net loss of $226,000, or $0.02 per share, as compared with net income of $446,000, or $0.04 per share, for the same period in 2022.

Revenue for the three months ended Dec. 31, 2023, was $602,000, down from $1 million a year earlier.

The company has declared a special dividend of $2.75 per share to shareholders of record on March 18. The special dividend will be paid on March 28.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BioCardia Receives Patent for Morph DNA Transseptal Delivery
BioCardia Receives Patent for Morph DNA Transseptal Delivery
Jul 17, 2024
08:45 AM EDT, 07/17/2024 (MT Newswires) -- BioCardia ( BCDA ) said Wednesday that it was granted a patent for its method for transseptal access to the heart using a steerable catheter based on the company's Morph DNA technology. The patent issued by the US Patent Office protects the company's products through 2035, BioCardia ( BCDA ) said. BioCardia's (...
Immutep Receives Dutch Regulatory Approval to Begin Human Testing of Potential Autoimmune Treatment
Immutep Receives Dutch Regulatory Approval to Begin Human Testing of Potential Autoimmune Treatment
Jul 17, 2024
08:45 AM EDT, 07/17/2024 (MT Newswires) -- Immutep ( IMMP ) said Wednesday it has received regulatory clearance from the Netherlands' ethics authority to begin human testing of its IMP761 potential autoimmune disease treatment. Immutep ( IMMP ) describes IMP761 as a LAG-3 agonist antibody to potentially treat rheumatoid arthritis, type 1 diabetes, and multiple sclerosis, among other autoimmune diseases....
Correction: Prologis Q2 Core Funds From Operations, Revenue Falls; Updates 2024 Core FFO Outlook
Correction: Prologis Q2 Core Funds From Operations, Revenue Falls; Updates 2024 Core FFO Outlook
Jul 17, 2024
08:32 AM EDT, 07/17/2024 (MT Newswires) -- Prologis ( PLD ) reported Q2 core funds from operations Wednesday of $1.34 per diluted share, compared with $1.83 a year earlier. Analysts polled by Capital IQ expected $1.07. Total revenue for the quarter ended June 30 was $2.01 billion, down from about $2.45 billion a year earlier. Analysts surveyed by Capital IQ...
United Lithium Kicks Off Exploration Programs in Finland
United Lithium Kicks Off Exploration Programs in Finland
Jul 17, 2024
08:47 AM EDT, 07/17/2024 (MT Newswires) -- United Lithium ( ULTHF ) said Wednesday that it commenced the 2024 exploration program in early June on five of its properties in Finland covering 105,000 hectares. The program aims to identify lithium-cesium-tantalum-type pegmatites across the Kietyonmaki project, as well as the Kannus, Kova, Kast and Salkola property reservations. Our exploration efforts will...
Copyright 2023-2026 - www.financetom.com All Rights Reserved